BACKGROUND. Proliferating cell nuclear antigen (PCNA) plays an important role in DNA replication and repair. The expression and potential utility of this marker in prostatic neoplasia is uncertain. With the development of this new caPCNA selective antibody, we explored the potential utility of this marker in prostate cancer. METHODS. Using a traditional primary Fab2′ rabbit anti-caPCNA antibody-HRP conjugated secondary anti-Fab2′ antibody format, the expression of the caPCNA was analyzed in prostate tissue from 89 radical prostatectomy specimens. The caPCNA expression was correlated with clinicopathologic characteristics. RESULTS. The fraction of cells staining positively with caPCNA antibody in prostatic adenocarcinoma (mean, 23%) was significantly higher than that in benign prostatic epithelium (mean, 2%; P<0.001) or high-grade prostatic intraepithelial neoplasia (PIN) (mean, 6%; P<0.05). Moreover, the intensity of caPCNA expression in prostatic adenocarcinoma (mean, 2.9) was significantly higher than that in benign prostatic tissue (mean, 0.7; P<0.001) or high-grade PIN (mean, 2.0; P<0.001). Benign prostatic epithelium showed only minimal or negative reactivity. There was significant correlation between the percentage of caPCNA expression and primary Gleason grade (P=0.01), and with Gleason score (P=0.02). Adenocarcinomas with positive vascular invasion had a significantly higher percentage of cells staining with caPCNA antibody (P<0.0001) and a higher intensity of caPCNA expression (P=0.04). CONCLUSIONS. Our data indicate that increased expression of the cancer-associated isoform of PCNA is common in prostatic adenocarcinoma and its precursor and may be a useful biomarker.
- Gleason grading
- High-grade prostatic intraepithelial neoplasia (PIN)
- Proliferating cell nuclear antigen (PCNA)
- Targeted therapy
ASJC Scopus subject areas